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Abstract: The newest measures for the control of harmful rodent populations are from the anticoagulant rodenticide group, which
are divided into 2 subgroups: first and second generations, and indandione derivatives. Non-target organisms are potentially at risk
of direct consumption of baits (primary hazard) and of eating poisoned rodents (secondary hazard). Anticoagulant rodenticides
inhibit the enzyme vitamin K-dependent carboxylase and thus impair the reactivation of vitamin K1, indirectly affecting physiological
blood coagulation. The diagnosis is made on the basis of clinical signs (massive hemorrhages), laboratory findings, and especially the
changes in coagulation markers (APTT, PT, TT, PCT, ACT, FDPs, and PIVKA). The specific antidote is vitamin K1. The general
prophylaxis consists of placing baits out of reach of animals, daily control of baits and dead rodents, which are to be timely removed.
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Introduction
Anticoagulant rodenticides are the largest group of
pesticides used for control of harmful rodents (1-4). For
the same purpose, derivatives of bromethalin,
cholecalciferol, and sodium fluoroacetate are also used
(5-7). However, their application is very limited while
inorganic rodenticides (phosphorus- and arseniccontaining) are not used. Hydroxycoumarin compounds
were discovered in the 1940s and have been in
continuous use since then (4,8,9). At present, they are
among the most commonly employed rodenticides and
therefore responsible for numerous accidents involving
humans and animals – both domestic and wild (10-33).
Classification of anticoagulant rodenticides.
Depending on their chemical structure, they are divided
into 2 main groups: hydroxycoumarine and indandione
(chlorophacinone, diphacinone, pindone, and valone)
rodenticides (Figure 1). Hydroxycoumarin rodenticides
are subdivided into first-generation (coumachlor,
coumafuryl, coumatetralyl, and warfarin) and secondgeneration (brodifacoum, bromadiolone, difenacoum,
difethialone and flocoumafen) compounds (Table 1)
(1,2,4).
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Figure 1. Chemical structure of anticoagulant rodenticides.

Routes of intoxication. Most commonly, domestic
and wild animals are intoxicated by intake of baits
containing anticoagulant rodenticides (primary
opportunity). The lack of odor and its pleasant taste due
to the saccharose content appear to be additional reasons
for the extensive incidences of intoxication in humans and
animals (10,11,14,34). Another main cause is the
ingestion of dead or alive poisoned rodents (secondary
opportunity) (14,32,33) by dogs, cats, swine, wild
mammals, or birds (4,9,10,12,20,30,32,35). The
number of incidents involving intoxications following a
direct skin contact (36) or through drinking water
(hydroxycoumarin derivatives are water soluble) (10,11)
are less frequent. The majority of reported cases in
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Table 1. Classification and toxicological features of anticoagulant rodenticides.
Acute oral toxicity LD50 (mg/kg)

Indandione

Second generation

Hydroxycoumarin

First generation

Group

Generic name
preparations

Commercial
formula

Chemical
Albino rats

Dogs

Coumachlor

Tomorin

C19H15ClO4

900

-

-

Coumafuryl

Kumatox, Ratafin

C17H14O5

0.4

6-40

-

Coumatetralyl

Rodentin

C19H16O3

16.5

-

-

Warfarin

Warfarat, Zoocoumarin

C19H16O4

58 (11-323)

20-50

1-5

Brodifacoum

Folgorat, Klerat, Talon, Rodend

C31H23BrO3

0.26

0.25-3.56

25 (11-33)

Bromadiolone

Lanirat, Contrac, Bromorat, Musal

C30H23BrO4

1.125

>10 (11-15)

>25

Difenacoum

Matrac, Rastop, Ratak, Silo

C31H24O3

1.8

50

100

Difethialone

Frap, Quell

C31H23BrO2S

0.56

5

>16

Flocounafen

Storm

C33H25F3O4

0.46

0.075-0.25

>10

Chlorophacinone

Delta, Patrol

C23H15ClO3

20.5

-

-

Diphacinone

Ratindan, Ratik

C23H16O3

3

3-7.5

14.7

Pindone

Pival, Tri-ban

C14H14O3

50

50

-

C14H14O3

-

-

-

Valone

humans are due to the first-generation hydroxycoumarin
preparation warfarin (37,38). It is used both as a
rodenticide and for prevention and treatment of diseases
related to enhanced blood hypercoagulability
(thromboembolism) (39).
Spontaneous intoxications with anticoagulant
rodenticides are reported in dogs (10,14,18,21,31,4044), horses (16,23), cats (20,41), wild animals (deer,
polecats, owls, eagles, falcons, ducks, martens, foxes,
etc.) (10,12,13,19,25,30,32-35), and humans
(39,45,46).
Experimental studies have been performed in
laboratory animals (47), dogs (48), cats (49,50), chicks
(51), and rabbits (52).
The biological half-life (T1/2) of warfarin, diphacinone,
and brodifacoum is 14-15 h, 15-20 days, and 120 days,
respectively (53).
The duration of the toxic effect after a single intake is
approximately 14 days for warfarin, 21 days for
bromadiolone, and 30 days for brodifacoum (53). These
data determine the need for a more prolonged therapy –
usually more than 1 month. A single intake of secondgeneration dioxycoumarin preparations is sufficient to
cause hemorrhages unlike first-generation substances. In
238

Cats

the latter group, the clinical effects are generally
observed after a repeated treatment (41).
Anticoagulant rodenticides reach the highest blood
plasma levels in animals in 12 h following oral intake,
which is the highest in plasma protein up to 90%-95%
(53). The preparations from this group are metabolized
in the liver and excreted mainly with urine and partly with
faeces. Hydroxycoumarin compounds of the second
generation are more toxic compared to first generation
representatives (52).
Mechanism of the toxic activity (Figure 2). The
action mechanism of hydroxycoumarin and indandione
anticoagulant rodenticides is identical, which yields similar
clinical manifestations, hematological alterations or
abnormalities, and treatment schedule, regardless of the
preparation group (54,55). Anticoagulant rodenticides
inhibit the recycling of vitamin K1, a cofactor of primary
importance for postribosomal carboxylation (activation)
of blood clotting factors II (prothrombin), VII
(proconvertin), IX (Christmas factor), and X (StuartPrower factor), by the enzyme vitamin K-dependent
carboxylase, maintaining the active form of vitamin K
(41,49,50,55). By the enzyme vitamin K-dependent
carboxylase, the active vitamin K is transformed into an
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inactive factors II, VII, IX, X
proteins S, C, Z

active factors (II, VII, IX, X)
proteins S, C, Z

glutamate

gamma carboxyglutamate
Vitamin K-dependent
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CO2+O2

OH

O

CH3
Vitamin K1
hydroquinone
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CH3
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R

R
OH

O
Vitamin K epoxide
reductase

Vitamin K reductase
O
CH3
inhibition

R

inhibition

O
Vitamin K quinone
(active)
Figure 2. Mechanism of the toxic effect of anticoagulant rodenticides. (Buckle) (55).

inactive epoxide that is thereafter reconverted into
vitamin K (vitamin K quinone), by the enzyme vitamin K
epoxide reductase. In the next step, the vitamin K
reductase converts vitamin K quinone into vitamin K1
hydroquinone that is integrated again in the carboxylation
cycle of blood clotting factors II, VII, IX, and X. Then the
enzyme vitamin K reductase converts vitamin K quinone
into vitamin K1 hydroquinone that enters once again the
carboxylation cycle of blood clotting factors II, VII, IX, and
X (55).
Anticoagulant rodenticides inhibit vitamin K epoxide
reductase, resulting in a lack of active vitamin K. This
mechanism contributes to blood clotting factors (II, VII,
IX, and X) that are not carboxylated and remain
nonfunctional (1,4,52-55). Because anticoagulant
rodenticides do not block these factors, their
concentrations in blood decrease about 12-24 h after the
intoxication coinciding with the first massive bleeding
episodes (20,41,44,47,49,50).
Clinical signs. The initial symptoms are general and
non-specific – somnolence, weakness, pale mucosa,
decreased (anorexia) or lacking appetite (arexia),
frequent urination (polyuria), increased thirst
(polydipsia), decreased locomotion and perception, and
rapid and easy exhaustion (12,19,28,29,31,33,41,51).

The data about rectal body temperature (BT) are
contradictory. Petterino et al. (28) reported decreased
BT, while Binev et al. (14) reported hyperthermia. These
data result from the application of various doses and
types of toxic compounds, but depend mostly on the
stage of intoxication. In the early phase, hypothermia is
rather encountered and at a later stage (after 2-3 days)
BT increases (14). The findings about the changes in
heart and respiratory rates are however uniform. All
investigators report tachycardia and polypnea with
dyspnea in spontaneous or experimental intoxications,
regardless of the animal species, the amount or the type
of the toxic substance, and the stage of intoxication
(21,23,29,45). Other clinical symptoms are bloody feces
(hematochezia, melena) (14,20,22), hemorrhages
(petechiae and ecchymoses) on the skin and mucosa
(16,20,29), hyphema (hemorrhages in the anterior eye
chamber between the cornea and the iris) and petechial
hemorrhages in conjunctivae (20,23,45), vomiting and
hematemesis (vomiting of blood) (20,21), nasal bleeding,
vaginal bleeding, and ear bleeding (16,20-22), dysuria,
and hematuria (21,23,45). The presence of pulmonary
edema, intrapulmonary and pleural hemorrhages
(20,23,26-28,41), correlated with the observed 2-sided,
air- and blood-containing nasal discharges (14,21,31).
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Our clinical observations (14) showed that almost
always, at a later stage of the intoxication (after 1 week)
in dogs, a bilateral symmetrical enlargement of the
abdomen was observed, frequently accompanied by
prolapse of the ventral abdominal wall and lordosis of the
vertebral column, resulting from hemorrhagic effusion
(ascites). This is the cause of the decreased absolute
cardiac dullness determined by percussion and the
dullness in the ventral parts of the lung field with a
horizontal upper limit, moving when the anterior part of
the body is being lifted (pleural effusion). The patients
frequently adopt the posture of a sitting dog. The
formation of massive hematomas after venipuncture is
also very characteristic.
Blood laboratory analysis. It is essential for the
precise and confident diagnosis of anticoagulant
rodenticide intoxication in animals (55).
a) Hematological abnormalities – anemia and
hypochromasia (hypochromic anemia), decreased
haematocrit values, leukocytosis with neutrophilia,
thrombocytopenia, enhanced erythrocyte sedimentation
rate, and decreased mean corpuscular volume
(14,16,20,21,29).
b)
Clinical
biochemistry
abnormalities.
Hypoproteinemia, hypoalbuminemia, hyperglycemia,
bilirubinemia, increased urea concentration, and enhanced
activities of alanine aminotransferase, alkaline
phosphatase,
and
gamma
glutamyltransferase
(14,16,19,20,43).
c) Coagulative profile abnormalities (Table 2).
These are prolonged activated partial thromboplastin

time (APTT), prothrombin time (PT), thrombin time
(TT), partial thromboplastin time (PTT), activated
clotting time (ACT), increased fibrin degradation
products’ concentration (FDPs), decreased amounts of
factors II, VII, IX, and X, increased fibrinogen and
increased values of the PIVKA (protein induced by vitamin
K antagonism or absence) test, specific for this type of
intoxication (14,20,21,29,31,36,48).
d) Changes in urine. Proteinuria, hematuria, and
plenty of erythrocytes in the sediment (20,42,56).
Gross pathology changes. The most characteristic
changes related to intoxication with anticoagulant
rodenticides are extensive, generalized, and multiple
hemorrhages. In the thorax, pleural, intrapulmonary, and
pericardial bleedings are observed (26,27,57),
pulmonary infiltrations, hemomediastinum (28,31),
cardiac tamponade (20,23,26,27), extensive hematomas
(causing obstruction of the trachea) (15,26,57), thymus
gland hemorrhages, subdural and cerebral bleedings,
vaginal and uterine hemorrhages and hematomas,
gastrointestinal bleeding and hemoperitoneum (57),
subcutaneous hemorrhages and abdominal hematomas
(27,57), hemorrhages and hematomas in the renal
parenchyma and bilateral hydronephrosis (42), bleedings,
hematomas and dystrophic damage of liver parenchyma
(18,42).
First-generation
dioxycoumarin
anticoagulant
rodenticides provoke the calcification of blood vessels (of
aorta, liver, mesenterial, femoral, renal, and other
arteries) and heart valves and tracheobronchial
calcification (45).

Table 2. Changes in blood clotting factors in dogs with spontaneous intoxication by anticoagulant rodenticides.
Factor
(s)

Normal values
(Schmid and von Forstner)
(60)

Bromadiolone
(Binev et al.)
(14)

Bromadifacoum
(Petrus and Henik)
(27)

Bromadifacoum
(Petrus and Henik)
(18)

ACT

<110

182

<67

225

APTT

12-16

86

36

-

PT

>150

10-14

122

-

PIVKA

<25

148

-

-

TT

7-12

82

327

-

Legend: ACT – activated clotting time, APTT – activated partial thromboplastin time, PT – prothrombin time, PIVKA –
protein induced by vitamin K antagonism or absense, TT – thrombin time.
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Treatment. The administration of emetics and active
charcoal suspension are recommended in the first 4 h of
the intoxication (4,40,43,58,59). At the time of the
appearance of clinical signs, it is necessary to begin the
specific antidote therapy. It consists in the application of
high doses of vitamin K1 (39,58-60). In dogs, the
preparation is applied perorally at average doses of 1.52.5 mg/kg twice daily (4). In small canine breeds, cats,
exotic animals, and birds, the doses could be increased to
4-5 mg/kg. In large dog breeds, the therapy begins with
low doses of 1.5-2 mg/kg (4,19,40,43). In cats, the dose
could reach 7 mg/kg (20). When administered orally, in
order to increase its absorption, it is given together with
food (40,43). The parenteral administration of vitamin
K1 is not recommended because of the potential risk of
anaphylactic reactions (58). Vitamin K3 is not effective in
such intoxications and therefore is not used (4,40). In
emergency cases, especially following intoxications with
second-generation hydroxycoumarin anticoagulant
rodenticides, vitamin K1 should be applied subcutaneously
at a dose of 5 mg/kg at several sites after the stabilization
of the patient via transfusion of whole blood or blood
plasma (39,58). As its effect occurs very rapidly, to
restore the activity of vitamin K-dependent blood clotting
factors, the next application of vitamin K1 is after 12 h
and applied only orally at 2.5-5 mg/kg once per 24 h for
3-6 weeks (4,19,40,43). If prothrombin time remains
considerably prolonged after that period, the treatment is
continued for another 2 weeks (4,40,43,58).
In large animals (horses, cattle, etc.), the parenteral
(intramuscularly or subcutaneously) use of vitamin K1 is
more appropriate. In ruminants, it is used subcutaneously
at 1-2 mg/kg. In these species, the application of vitamin
K3 is less effective. In horses, vitamin K1 is applied
intramuscularly at 0.5-2.5 mg/kg. The administration of

K3 in this species results in a significant renal damage
(4,16). The duration of the treatment with vitamin K1 is
different, but almost all investigators state that it should
be pursued for at least a month (47,58). This period
depends on many factors: type and amount of ingested
rodenticide, animal species, route of intake, but mostly on
the rapid and precise diagnosis and the timely,
appropriate treatment. The recovery of the ACT factor is
a sign that the animal has overcome the intoxication by
anticoagulant rodenticides (4,40,43).
Prognosis. It is poor. It is supposed that if the animals
overcome the acute coagulopathy, the prognosis after day
2 is more favorable (4). Our clinical observations (14)
support the idea that even when the symptoms of
intoxication in dogs have disappeared, in most instances,
there is a prerequisite for a periodically recurring ascites
as a result of dystrophic damage to the liver parenchyma.
Prevention. The prevention of intoxication in animals
requires the placement of baits in inaccessible places. A
daily control is needed on both baits and on dead rodents,
the latter being regularly removed and buried.

Conclusion
The intoxications with anticoagulant rodenticides in
animals are relatively frequent. To date, these
preparations have been the only means for effective
control of rodent populations, and therefore they have
caused intoxications mainly in pets (dogs and cats) and
wild animals by ingestion of baits. Therefore, the
principles of diagnostics, treatment, and prevention
should be observed with regard to the protection of
animals against these types of intoxication.
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